This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM.


 

Speaker:

Neal Lindeman, MD

Moderator:

Anna Yemelyanova, MD


The advent of targeted therapies based on predictive biomarkers has dramatically altered the role of the molecular pathologist in lung cancer patient care. This webinar reviews the new recommendations published in the revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines (Lindeman et al., J Mol Diagn, 2018). This webinar, reviewing the evidence and logic behind the new recommendations, is designed for molecular pathologists, pathologists, oncologists, clinicians, trainees, and multidisciplinary tumor boards to help improve NSCLC patient care. Topics to be covered include recommendations regarding new predictive biomarkers; recommendations for testing for EGFR and ALK TKI resistance; and recommendations regarding new testing methodologies including the use of multiplexed genetic sequencing panels (e.g., NGS testing) to identify other treatment options beyond EGFR, ALK, and ROS1 as well as cell-free circulating DNA testing for EGFR resistance mutations. The revised 2018 CAP/IASLC/AMP lung cancer predictive biomarker guidelines will impact the daily practice of molecular pathologists and clinicians in the care of nearly 150,000 eligible lung cancer patients each year, regardless of whether in a community practice, a large reference lab, or an academic setting, and regardless of their level of expertise or experience.

This webinar is part 1 of a five-part series aimed a breaking down barriers to NSCLC testing and treatment. If you'd like more information about the series go here


Practice Guideline Available Here

Duration: 1 hr

Level of Instruction: Basic

Supported by an educational grant from AstraZeneca


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by December 31, 2020

 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

   

 
Course Information
Course Date:
May 29, 2018
Course Objectives
  • Review the new recommendations for lung cancer biomarker testing, their impact on patient care, and appropriate methods of testing (pre-analytic, analytic and post analytic actions).
  • Evaluate how the evidence published since the original 2013 guideline have been impacted by new observations and evidence since the first guideline.
  • Explain how molecular pathologists would utilize the recommendations in clinical practice using a case-based learning approach.
Pre-Test for Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision
Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision
Speaker Information
Neal I. Lindeman MD   [ view bio ]
Post-Test for Molecular Testing Guidelines for Selection of Lung Cancer Patients - Revision
QA Session
Individual topic purchase: Selected
Products
Lindeman Presentation
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00